Senti Biosciences Inc
shares are trading higher by 102.6% to $0.56 during Monday’s session after the company was awarded $8 million from the California Institute for Regenerative Medicines, which will support the ongoing development of SENTI-202.
The company says SENTI-202 is an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial aims to provide initial efficacy data by the end of 2024 and durability data in 2025.
The trial, enrolling adult patients with specific hematologic malignancies in the US and Australia, evaluates two dose levels of SENTI-202 cells administered in cycles after disease-specific conditioning.
SNTI has a 52-week high of $1.09 and a 52-week low of $0.21.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.